以色列的制药和生物技术市场以高研发支出和令人印象深刻的国际影响力而享誉...查看全文
Kamada(KMDA)03-06 20:15
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-020275 Act: 34 Size: 4 MB 网页链接查看全文
Kamada(KMDA)03-06 20:05
$Kamada(KMDA)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-020272 Act: 34 Size: 18 MB 网页链接查看全文
Kamada(KMDA)02-28 20:05
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-017739 Act: 34 Size: 19 KB 网页链接查看全文
Kamada(KMDA)02-15 06:05
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-24-014144 Act: 34 Size: 78 KB 网页链接查看全文
Kamada(KMDA)02-13 01:45
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000467 Act: 34 Size: 79 KB 网页链接查看全文
Kamada(KMDA)2023-12-29 02:25
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-23-003994 Act: 34 Size: 82 KB 网页链接查看全文
Kamada(KMDA)2023-12-28 22:35
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-099085 Act: 34 Size: 13 KB 网页链接查看全文
Kamada(KMDA)2023-12-19 19:15
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-23-003931 Act: 34 Size: 78 KB 网页链接查看全文
Kamada(KMDA)2023-12-06 20:05
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-093276 Act: 34 Size: 85 KB 网页链接查看全文
逍遥投资派2023-05-21 00:00
$Kamada(KMDA)$ 5年来营收基本在1亿以上窄幅波动,营业利润则在2021年突然转亏,2022年也仅恢复到2020年的1/4,净利润近两年则连续小幅亏损。
目前市值2.2亿,即使以2018年最高的0.22亿净利润计算,市盈率也达到了10,缺乏吸引力。查看全文
平凡Stone2021-02-03 23:06
$Kamada(KMDA)$ ARK fund Israel
Kamada Ltd.是一家通过销售市场现有罕见组合药物产品的,等离子体衍生蛋白质疗法公司。公司开发和生产的专业衍化蛋白质疗法产品,在一些新兴市场上,这些产品通过美洲和欧洲的战略合作伙伴被经营出售,或者通过当地的经销商直接在当地销售,该公司的旗舰产品是“...查看全文
财报提醒2020-02-06 07:39
$Kamada(KMDA)$ Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2019, prior to the open of the U.S. financial markets on Wedne...查看全文
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-064751 Act: 34 Size: 18 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-056768 Act: 34 Size: 370 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-056318 Act: 34 Size: 24 KB 网页链接
$Kamada(KMDA)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001178913-23-002052 Act: 34 Size: 358 KB 网页链接
$Kamada(KMDA)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-042696 Act: 34 Size: 309 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-042535 Act: 34 Size: 6 MB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-042526 Act: 34 Size: 26 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-042523 Act: 34 Size: 30 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-040643 Act: 34 Size: 20 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-040126 Act: 34 Size: 34 KB 网页链接